Keyphrases
Immunogenicity
90%
Indonesia
75%
Indonesian children
44%
Malaysian Adults
44%
Typhoid Vaccine
36%
Jakarta
33%
Vi-DT
33%
Recombinant Vaccine
33%
Indonesian
31%
Second Dose
25%
COVID-19
25%
Phase II Study
25%
Urban Dwelling
22%
Seroprevalence
22%
Randomized Clinical Trial
22%
Primary Infection
22%
Diphtheria Toxoid
22%
Dengue
22%
Adjuvanted
22%
CpG 1018
22%
Alum
22%
Vaccination
21%
Adverse Events
16%
Revaccination
16%
Conjugate Vaccine
15%
Fever
14%
Immunogenic
14%
Local Reaction
14%
Systemic Response
14%
Risk Factors
13%
Serious Adverse Events
13%
Phase I Study
13%
Demographic Factors
12%
Confidence Interval
12%
Safety Assessment
12%
Neutralizing Antibodies
12%
Vi Polysaccharide Vaccine
12%
Blood Samples
12%
Salmonella Typhi (S. Typhi)
12%
Phase II Trial
12%
Cut-off Score
12%
Young children
12%
Geometric Mean Titer
11%
Seroconversion
11%
Typhoid Fever
11%
Growth Delay
11%
Immunization Schedule
11%
Expanded Program on Immunization
11%
Multicenter Trial
11%
Environmental Performance Management
11%
Pharmacology, Toxicology and Pharmaceutical Science
Immunogenicity
100%
Adverse Event
47%
Conjugate Vaccine
44%
SARS Coronavirus
33%
Typhoid Vaccine
25%
Hepatitis B
22%
Primary Infection
22%
Recombinant Protein
22%
Protein Subunit Vaccine
22%
Diphtheria Toxoid
22%
Seroprevalence
22%
Dengue
22%
Randomized Clinical Trial
22%
Typhoid Fever
18%
Neutralizing Antibody
17%
Prevalence
16%
Clinical Trial
16%
Polysaccharide
14%
Pandemic
14%
Infection
14%
Diseases
12%
Diphtheria
11%
2,5-Dimethoxy-4-iodoamphetamine
11%
Chronic Disease
11%
Recombinant Vaccine
11%
Diphtheria Vaccine
11%
Prospective Cohort Study
11%
Salmonella Enterica Serovar Typhi
11%
Developmental Delay
11%
Placebo
11%
Stunting
11%
Tropical Disease
11%
Haemophilus
11%
Influenza B
11%
Myalgia
10%
Normal Human
8%
Interleukin 2
7%
COVID-19 Vaccine
6%
2009 H1N1 Influenza
5%
Influenza A Virus (H3N2)
5%
Hepatitis B Antigen
5%
Triple Vaccine
5%